- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Oric Pharmaceuticals Inc.
Headquarters: South San Francisco, CA, United States
Website: http://oricpharma.com
Year Founded: 2014
Status: Public
Industry Sector: HealthTechnology
CEO: Jacob M. Chacko, MD, MBA
Number Of Employees: 115
Enterprise Value: $316,101,476
PE Ratio: -2.7
Exchange/Ticker 1: NASDAQ:ORIC
Exchange/Ticker 2: N/A
Latest Market Cap: $378,188,704
BioCentury | Jan 18, 2025
Data Byte
Takeout news crowns JPM’s winning stocks
Gainers, decliners among companies presenting at this week’s J.P. Morgan Healthcare Conference
BioCentury | Aug 7, 2024
Management Tracks
Flagship’s Quotient names co-founder Campbell CSO
Plus: Cellectis hires Kilcoyne and more from Helio, Sapphiros, Pharmanovia, the ADA and Outcome Capital
BioCentury | Aug 7, 2024
Management Tracks
Flagship adds White House veteran Panjabi
Plus: Biogen alum Radhakrishnan joins Sofinnova Investments, and updates from Bicycle, iTeos, Fennec, Faron and ORIC
BioCentury | Jan 27, 2024
Finance
Public equity roundup: CG, ArriVent IPOs stoke optimism for growing queue
Plus: Follow-ons for Sagimet, Tourmaline and Adicet, and PIPEs for Kura, ORIC and CalciMedica
BioCentury | Dec 23, 2022
Deals
Dec. 22 Quick Takes: Mersana picks Merck KGaA for its third ADC deal of 2022
Plus: Lilly builds on genetic medicine focus with ProQR deal and Stifel buying Torreya; Gilead; lecanemab; ORIC-Pfizer and more
BioCentury | Mar 23, 2022
Deals
March 22 Quick Takes: Pfizer to supply UNICEF with Paxlovid
Plus Argenx’s efgartigimod meets and updates from Oric, Aligos, ITM and more
BioCentury | Dec 1, 2021
Management Tracks
Grauer becomes CMO at Federation Bio
Plus: LabGenius, 23andMe, Vifor, Immunovia, Forma and more
BioCentury | Oct 26, 2020
Emerging Company Profile
Serial dealmaker Glick to lead cancer start-up Scorpion with familiar VCs supplying $108M
Syndicate that backed IFM invests in experienced precision oncology team
BioCentury | Oct 7, 2020
Finance
With life sciences now a ‘core’ investment area, General Atlantic picks a global head
Brett Zbar, an ex-Foresite partner, will lead the firm’s international life sciences team
BioCentury | Aug 3, 2020
Finance
After raising crossover-heavy $70M round, p53 play PMV likely one of the next preclinical IPOs
Items per page:
1 - 10 of 40